Why Calibrate Type I Error by Simulation?
An adaptive trial’s final conclusion can depend on interim data, stopping decisions, treatment allocation, and the analysis applied at the end. A nominal significance level alone does not establish how often the complete design will produce a false-positive conclusion. Type I error calibration asks a design-level question: when the relevant null hypothesis is true, how often does the full trial algorithm nevertheless make the claim?
Simulation addresses that question by repeatedly generating hypothetical trials under specified null scenarios and applying the trial’s actual decision rules to each one. The result is an estimate of a probability, not a guarantee that every possible implementation or population will attain the target. Calibration is informative only when the simulated scenarios, data-generating process, and algorithm represent the intended design.
The event \(A_s\) must be specified before examining simulation results. For a single primary claim, it may be “the final analysis declares the treatment effective.” If a trial can make several confirmatory claims, the event may instead be “at least one claim is made for which the corresponding null is true.” The latter definition reflects the trial-level false-positive risk when the design’s stated error target applies to any false claim.
What Must Be Simulated?
A replicate must reproduce the trial as it would actually be run, not just its final statistical test. Generate the data under scenario \(s\), apply the enrollment and allocation rules, evaluate interim information at the planned looks, execute any stopping or adaptation rules, and apply the final decision rule. Record whether the prespecified false-positive event occurred. If a trial stops early, that stopping is part of the algorithm; it is not a reason to omit the replicate.
The scenario must make the relevant null true and specify the other features needed to generate outcomes. These may include baseline risk, outcome variability, accrual, missingness, delayed outcomes, and treatment effects on outcomes other than the null effect, as appropriate to the design. A null hypothesis does not by itself specify a complete data-generating model. Simulating the null while using unrealistic nuisance parameters can produce a precise estimate of the wrong operating characteristic.
For a family of possible null configurations, calibration should match the intended error-control claim. Under the global null, all tested treatment effects are null. A satisfactory rate under that one configuration is a weak check: it does not establish control when some effects are nonzero but other tested nulls remain true. Checking the maximum false-positive rate across configurations that include true null hypotheses assesses the more demanding form of control often called strong control. Which configurations are needed depends on the claims and error target specified for the trial.
State exactly what counts as a false-positive conclusion, identify the null scenarios, and record the prespecified error target \(\alpha\).
For each scenario, simulate independent trial data and execute every adaptive and inferential rule in its planned order.
Record one indicator per replicate according to the event definition; do not count interim signals as final claims unless the protocol makes them claims.
Report scenario-specific rates, identify the worst relevant scenario, and account for finite simulation variability before judging calibration.
Why the Simulation Rate Estimates the Error Probability
Under a fixed scenario, suppose the \(R\) simulated replicates are independent and each faithfully follows the same data-generating process and trial algorithm. Then each indicator \(Y_{rs}\) is Bernoulli with probability \(\theta_s\): it equals 1 with probability \(\theta_s\), and 0 otherwise. The estimator is the average of these indicators.
Thus the simulated rate is unbiased for the scenario-specific error probability under the simulation model. Independence also gives a direct description of its Monte Carlo variability:
This calculation explains why a simulated rate can differ from the underlying probability, especially when \(R\) is modest. Repeating the same simulation code with a different random seed can yield a different count. The estimated standard error is commonly approximated by \(\sqrt{\hat{\theta}_s(1-\hat{\theta}_s)/R}\); it describes simulation noise, not uncertainty about whether the scientific null is true. A small estimate alone is not proof that the design meets its target.
Worked Example: A Single Null Scenario Near the Target
Suppose a hypothetical adaptive trial has a prespecified trial-level Type I error target of \(\alpha=0.05\). In each of \(R=2{,}000\) simulated trials under a specified null scenario, the complete algorithm is run. A false-positive event is recorded only if the final efficacy rule declares benefit. That event occurs in 82 replicates.
The estimated rate is
The simulated estimate is 4.1%, below the 5% target. To gauge its simulation variability, the plug-in standard error is
A prespecified screening rule might require the estimate plus two estimated standard errors to be no greater than the target. Here \(0.041+2(0.00443)=0.0499\), just below 0.05. By that approximate rule, this run passes narrowly. This is a screening calculation, not a formal confidence statement or proof of control; its approximation and decision threshold should be chosen before results are reviewed. The result supports calibration only for the null scenario and implementation actually simulated.
Calibration Across Scenarios and Tuning
A design’s error probability can change across null scenarios even when the null effect itself remains zero. For example, event rates, nuisance parameters, or the timing of available information may affect how often an adaptive rule reaches a final decision. Report scenario-specific estimates rather than averaging them into one reassuring number. If the target applies to every prespecified scenario, the relevant comparison is each rate against the target, with particular attention to the largest rate.
Calibration may involve adjusting a decision threshold or another prespecified design feature. Because trying multiple settings can make the chosen setting look better by chance, distinguish development from validation. Use development simulations to identify a candidate rule. Then freeze that rule and evaluate it with fresh, independent simulation replicates under the calibration scenarios. Reusing the same simulated outcomes to tune and validate can understate how often the selected rule will exceed its target in new runs.
Worked Example: Checking More Than the Global Null
A hypothetical trial makes confirmatory claims about two treatments. Its target is 0.05 for the probability of making at least one false claim. Investigators simulate 1,000 trials for each of two configurations. In the global-null configuration, both treatment effects are null and 37 replicates produce at least one claim. In a partial-null configuration, treatment A has an effect but treatment B’s null remains true; 63 replicates produce a claim for B.
Under the global null, the simulated trial-level rate is \(37/1{,}000=0.037\), or 3.7%. In the partial-null configuration, the relevant false-positive rate for the still-true null is \(63/1{,}000=0.063\), or 6.3%. The second estimate exceeds the target. Therefore, the design has not demonstrated calibration across these configurations, even though its global-null estimate is below 5%.
The event definition matters here. A claim for treatment A in the partial-null configuration is not a false positive if A’s effect is truly nonzero; counting it as one would misclassify the outcome. The simulation record must identify which nulls are true in each scenario and whether the final claims reject those nulls. This example also shows why simply reporting the fraction of trials with any claim is insufficient when some claims may be true.
Worked Example: Validating a Tuned Decision Threshold
In a hypothetical design, development simulations lead investigators to choose a more stringent final decision threshold. They then freeze the rule and run 2,500 fresh simulations under the prespecified null scenario. The final rule produces 115 false-positive conclusions.
The validation estimate is
This is 4.6%, below a 5% target. The estimated standard error is
Using the illustrative two-standard-error screen from the preceding example gives \(0.046+2(0.00419)=0.0544\), above 0.05. Thus the point estimate meets the target, but this conservative screening rule does not provide a clear pass. The appropriate next step is determined by the prespecified calibration plan—for example, increasing the simulation effort or revisiting the candidate rule—not by switching to the more favorable development result. Any retuning should be followed by a new validation run.
Diagnostics, Alternatives, and Limitations
A surprising rate should prompt checks of both the simulation and the design. Inspect whether all planned interim looks occurred at the correct information times, whether stopping boundaries and adaptation rules were implemented in the intended order, and whether the final decision rule matches the protocol. Confirm that null scenarios truly set the relevant effects to zero and that any nuisance parameters and outcome dependencies are generated as specified. Verify that every replicate contributes one outcome indicator, including trials that stop early or fail to reach a final analysis.
A simulation estimate can be numerically stable and still be misleading if the code omits a pathway, the generated data are unrealistic, or the tested scenarios are incomplete. Independent code review, tests on simple cases with known answers, and comparison of simulated intermediate quantities with their expected behavior can help detect implementation errors. Large disagreement among repeated batches may indicate inadequate simulation effort or a coding problem; it should not be resolved by selectively reporting the most favorable batch.
When the design has a simple fixed-sample test with known assumptions, analytic calibration may provide an exact or well-established reference and can be easier to inspect. Approximate formulas can also be useful for simple designs, but may not capture complex adaptation, stopping, or multiplicity. Simulation is more flexible because it can apply the full algorithm to realistic scenarios, but it depends on correct code and a credible data-generating model. These approaches are complementary: where a simpler analytic case is available, it can serve as a check on simulation code.
Calibration has limits. No finite collection of scenarios establishes error control for every possible population or model departure. Scenario selection should therefore be scientifically justified and recorded, and the conclusion should name its scope. Nor does a simulated rate below the target establish good performance under alternatives; that is a different operating characteristic. The target, event definition, scenarios, simulation count, and pass criterion should be specified before the final validation results are examined.
Common Mistake
Wrong reasoning: “The observed false-positive rate was 4.8%, below the 5% target, so the design is proven to control Type I error.”
Correction: A simulated rate is an estimate subject to Monte Carlo variation, and it applies only to the scenarios and algorithm simulated. Compare it with the target using a prespecified criterion that recognizes simulation variability, examine all relevant null configurations, and state the scope of the conclusion. A rate just below the target is not automatically convincing evidence of calibration.
Check Your Understanding
Answer each question, then compare your reasoning with the brief solutions.
- A simulation under one null scenario produces 24 false-positive conclusions in 600 replicates. What is the estimated Type I error, and how does it compare with a target of 0.05?
- Why might a rate below 0.05 under the global null fail to establish control when a trial tests two treatments?
- In a partial-null scenario, treatment A has a real effect and treatment B’s effect is zero. Which claim counts toward the false-positive event for B?
- Why should fresh simulations be used to validate a decision threshold selected through development simulations?
Solutions. (1) \(24/600=0.04\), or 4%; the point estimate is below 5%, but simulation variability and scenario coverage still matter. (2) The error rate may be higher in a configuration where one treatment effect is nonzero but another tested null remains true; a global-null check alone does not assess that configuration. (3) A final claim that treatment B is effective counts as a false positive because B’s null is true; a true claim for A does not. (4) Reusing development outcomes can make a selected threshold appear better than it performs on new replicates, so independent validation better evaluates the frozen rule.